

TRUST BOARD IN PUBLIC		Date: 27th October 2016	
		Agenda Item: 4.1	
REPORT TITLE:		Infection Prevention & Control & Antimicrobial Stewardship (IPCAS) Annual Report	
EXECUTIVE SPONSOR:		Dr Des Holden Medical Director	
REPORT AUTHOR (s):		Ashley Flores, Dr Karen Knox, Amy Lee, Dr Donald Lyon, Ruth Bradburn. Jill Clarke	
REPORT DISCUSSED PREVIOUSLY: (name of sub-committee/group & date)		IPCAS Group and SQC 01/09/16	
Action Required:			
Approval (√)	Discussion ()	Assurance (√)	
Purpose of Report:			
This Infection Prevention, Control & Antibiotic Stewardship (IPCAS) Annual Report and Programme for Surrey & Sussex Healthcare (SASH) NHS Trust has been prepared for and is submitted to the Trust Board by the IPCAS Team on behalf of the Trust's IPCAS Group. This report summarises the annual achievements, developments, performance and standards by the Trust and its staff in key areas and against key objectives relating to infection prevention and control and prudent antibiotic prescribing.			
Summary of key issues			
<i>Clostridium difficile infection (CDI)</i>			
In 2015/16 the CDI target objective was set at no more than 15 Trust-apportioned cases. Of the 34 Trust-apportioned cases identified in year, 3 cases were counted towards the aggregate number of cases, on the basis of there being an identifiable lapse in Trust-delivered care. The target objective was therefore achieved in year.			
Management of diarrhoea has been included as a work-stream within the SASH Plus initiative in the Trust.			
MRSA blood stream infection (MRSA BSI)			
In 2015/16 the MRSA target objective, as in previous years, was zero avoidable Trust-apportioned cases. Of the 2 Trust apportioned cases, both were investigated using the national Post Infection Review tool within the required timeframe of 14 days. One case was felt to be unavoidable; the other was an avoidable case relating to a peripheral venous cannula.			
Recommendation:			
The report is submitted to the Board for Approval & Assurance.			
Relationship to Trust Strategic Objectives & Assurance Framework:			
SO1: Safe – Deliver safe high quality and improving services which pursue perfection and be in the top 20% against our peers			
Corporate Impact Assessment:			
Legal and regulatory impact	<ul style="list-style-type: none"> Health & Social Care Act (2008) - Code of Practice for Infection Prevention & Control 		

	<ul style="list-style-type: none"> • CQC requirements
Financial impact	There are financial penalties for MRSA blood stream infection (BSI) and <i>Clostridium difficile</i> cases (where there are over 15 'lapses in care).
Patient Experience/Engagement	
Risk & Performance Management	
NHS Constitution/Equality & Diversity/Communication	N/A
Attachment:	
IPCAS Annual Report 2015/16	